Oncogenic kras desensitizes colorectal tumor cells to epidrmal growth factor receptor inhibition and activation

Neoplasia

Volumn 12, Issue 6, 2010, Pages 443-452

  van Houdt, Winan J ^a   Hoogwater, Frederik J H ^a   de Bruijn, Menno T ^a   Emmink, Benjamin L ^a   Nijkamp, Maarten W ^a   Raats, Danielle A E ^a   van der Groep, Petra ^a   van Diest, Paul ^a   Borel Rinkes, Inne H M ^a   Kranenburg, Onno ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; OSI 1774; PROTEIN C FOS; PROTEIN KINASE B; RHO KINASE; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR; KRAS PROTEIN, HUMAN; MESSENGER RNA; ONCOPROTEIN; RAS PROTEIN;

ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL ADHESION; CELL MEMBRANE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG MECHANISM; ENDOCYTOSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE DELETION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN LOCALIZATION; RECEPTOR BLOCKING; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; ENZYME IMMUNOASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM; ONCOGENE; PHOSPHORYLATION; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TUMOR CELL CULTURE; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL MEMBRANE; COLORECTAL NEOPLASMS; EPIDERMAL GROWTH FACTOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLUORESCENT ANTIBODY TECHNIQUE; GENES, FOS; HUMANS; IMMUNOENZYME TECHNIQUES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED;

EID: 77953216750     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.92088     Document Type: Article

References (30)

1. Dignass AU and Sturm A (2001). Peptide growth factors in the intestine. Eur J Gastroenterol Hepatol 13, 763-770.
2. Kinzler KW and Vogelstein B (1996). Lessons from hereditary colorectal cancer. Cell 87, 159-170.
3. + mice. J Biol Chem 279, 43261-43272.
4. Roberts RB, Min L, Washington MK, Olsen SJ, Settle SH, Coffey RJ, and Threadgill DW (2002). Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc Natl Acad Sci USA 99, 1521-1526.
5. Nicholson RI, Gee JM, and Harper ME (2001). EGFR and cancer prognosis. Eur J Cancer 37(suppl 4), S9-S15.
6. O'Dwyer PJ and Benson AB III (2002). Epidermal growth factor receptor-targeted therapy in colorectal cancer. Semin Oncol 29, 10-17.
7. Radinsky R, Risin S, Fan D, Dong Z, Bielenberg D, Bucana CD, and Fidler IJ (1995). Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1, 19-31.
8. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, et al. (2008). Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26,1626-1634.
9. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, et al. (2009). Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27, 663-671.
10. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, et al. (2008). KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19, 508-515.
11. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, et al. (2008). K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359, 1757-1765.
12. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, et al. (2009). Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360, 1408-1417.
13. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, and Schilsky RL (2009). American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to antiepidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27, 2091-2096.
14. Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, Papadimitriou CA, and Murray S (2008). Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9, 962-972.
15. Jacobs B, De Roock W, Piessevaux H, Van Oirbeek R, Biesmans B, De Schutter J, Fieuws S, Vandesompele J, Peeters M, Van Laethem JL, et al. (2009). Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 27, 5068-5074.
16. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, et al. (2007). Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25, 3230-3237.
17. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, and Burgess AW (2003). Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 284, 31-53.
18. Shirasawa S, Furuse M, Yokoyama N, and Sasazuki T (1993). Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260, 85-88.
19. Smakman N, Veenendaal LM, van Diest P, Bos R, Offringa R, Borel Rinkes IH, and Kranenburg O (2005). Dual effect of Kras (D12) knockdownon tumorigenesis: increased immune-mediated tumor clearance and abrogation of tumor malignancy. Oncogene 24, 8338-8342.
20. Perreault N and Beaulieu JF (1998). Primary cultures of fully differentiated and pure human intestinal epithelial cells. Exp Cell Res 245, 34-42.
21. Kranenburg O, Verlaan I, and Moolenaar WH (2001). Regulating c-Ras function: cholesterol depletion affects caveolin association, GTP loading, and signaling. Curr Biol 11, 1880-1884.
22. Veenendaal LM, Kranenburg O, Smakman N, Klomp A, Borel Rinkes IH, and van Diest PJ (2008). Differential Notch and TGFbeta signaling in primary colorectal tumors and their corresponding metastases. Cell Oncol 30, 1-11.
23. Mosesson Y, Mills GB, and Yarden Y (2008). Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer 8, 835-850.
24. Sorkin A and Goh LK (2009). Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 315, 683-696.
25. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, et al. (2008). Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26, 5705-5712.
26. Quintela-Fandino M, Le Tourneau C, Duran I, Chen EX, Wang L, Tsao M, Bandarchi-Chamkhaleh B, Pham NA, Do T, Maclean M, et al. (2010). Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort. Mol Cancer Ther 9, 751-760.
27. Takezawa K, Okamoto I, Yonesaka K, Hatashita E, Yamada Y, Fukuoka M, and Nakagawa K (2009). Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells. Cancer Res 69, 6515-6521.
28. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, et al. (2004). Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351, 337-345.
29. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, and Mayer RJ (2004). Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22, 1201-1208.
30. Damstrup L, Kuwada SK, Dempsey PJ, Brown CL, Hawkey CJ, Poulsen HS, Wiley HS, and Coffey RJ Jr (1999). Amphiregulin acts as an autocrine growth factor in two human polarizing colon cancer lines that exhibit domain selective EGF receptor mitogenesis. Br J Cancer 80, 1012-1019.